NO971900L - Blandinger og behandling av multippel sklerose - Google Patents

Blandinger og behandling av multippel sklerose

Info

Publication number
NO971900L
NO971900L NO971900A NO971900A NO971900L NO 971900 L NO971900 L NO 971900L NO 971900 A NO971900 A NO 971900A NO 971900 A NO971900 A NO 971900A NO 971900 L NO971900 L NO 971900L
Authority
NO
Norway
Prior art keywords
disease
multiple sclerosis
treatment
autoantigen
myelin
Prior art date
Application number
NO971900A
Other languages
English (en)
Norwegian (no)
Other versions
NO971900D0 (no
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of NO971900D0 publication Critical patent/NO971900D0/no
Publication of NO971900L publication Critical patent/NO971900L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO971900A 1994-10-25 1997-04-24 Blandinger og behandling av multippel sklerose NO971900L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
NO971900D0 NO971900D0 (no) 1997-04-24
NO971900L true NO971900L (no) 1997-06-25

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971900A NO971900L (no) 1994-10-25 1997-04-24 Blandinger og behandling av multippel sklerose

Country Status (15)

Country Link
EP (1) EP0787147A1 (is)
JP (1) JPH10504039A (is)
AU (1) AU4278296A (is)
BR (1) BR9509438A (is)
CA (1) CA2203629A1 (is)
CZ (1) CZ122697A3 (is)
FI (1) FI971750A7 (is)
HU (1) HUT77047A (is)
IL (1) IL115766A0 (is)
IS (1) IS4466A (is)
NO (1) NO971900L (is)
PL (1) PL324091A1 (is)
SI (1) SI9520118A (is)
SK (1) SK51297A3 (is)
WO (1) WO1996012737A2 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
WO1997035193A1 (en) 1996-03-21 1997-09-25 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
NZ507901A (en) * 1998-05-05 2003-06-30 Corixa Corp Isolated myelin basic protein (MBP) for treating mutliple sclerosis
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
NZ546806A (en) 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2010024927A2 (en) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
AU2010234743A1 (en) * 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CN102781465A (zh) 2009-10-12 2012-11-14 生命生物实验室有限公司 用于治疗多发性硬化的组合物
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) * 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
EP3094341B1 (en) 2014-01-13 2019-10-02 Berg LLC Enolase 1 (eno1) compositions and uses thereof
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666080B1 (en) * 1987-06-24 2004-01-21 Brigham & Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
ES2144398T3 (es) * 1989-12-20 2000-06-16 Autoimmune Inc Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
AU651097B2 (en) * 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
AU3220693A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
HU220357B (hu) * 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
EP0650498B1 (en) * 1992-04-09 1998-09-09 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
KR960705038A (ko) * 1993-09-03 1996-10-09 스테시 엘. 채닝 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
WO1995008572A1 (en) * 1993-09-22 1995-03-30 The Board Of Trustees For The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
EP0752880A4 (en) * 1994-04-08 2000-08-09 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I
EP0752879A4 (en) * 1994-04-08 1999-07-21 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR TH2-ENHANCING CYTOKINES
EP0758902A1 (en) * 1994-05-10 1997-02-26 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
ATE172304T1 (de) * 1994-06-09 1998-10-15 Tno Alpha b crystallin zur verwendung in diagnose und therapie von autoimmunkrankheiten, besonders multipler skerose
ATE213499T1 (de) * 1994-11-18 2002-03-15 Neurocrine Biosciences Inc Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
IS4466A (is) 1997-04-17
BR9509438A (pt) 1997-12-23
SI9520118A (sl) 1998-08-31
WO1996012737A2 (en) 1996-05-02
FI971750A0 (fi) 1997-04-24
SK51297A3 (en) 1998-03-04
PL324091A1 (en) 1998-05-11
CZ122697A3 (en) 1997-09-17
NO971900D0 (no) 1997-04-24
HUT77047A (hu) 1998-03-02
CA2203629A1 (en) 1996-05-02
WO1996012737A3 (en) 1996-10-10
IL115766A0 (en) 1996-01-19
AU4278296A (en) 1996-05-15
EP0787147A1 (en) 1997-08-06
FI971750A7 (fi) 1997-06-24
JPH10504039A (ja) 1998-04-14

Similar Documents

Publication Publication Date Title
NO971900L (no) Blandinger og behandling av multippel sklerose
Neufeld et al. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes
RU2007102698A (ru) Композиции и способы лечения неврологических нарушений
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
US4818763A (en) Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
EP1918298A3 (en) Peptide
Petrov et al. Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
Ilyas et al. Cellular hypersensitivity to gangliosides and myelin basic protein in multiple sclerosis
Yamada et al. Bombesin-like immunoreactivity in human cerebrospinal fluid
Silfvast Prehospital resuscitation in Helsinki, Finland
Hashim Experimental allergic encephalomyelitis: activation of suppressor T lymphocytes by a modified sequence of the T effector determinant.
JP4160505B2 (ja) 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用
KR20080098488A (ko) Ｈｉｖ 치료
Janković et al. Enkephalinase-inhibitors modulate immune responses
US20080207500A1 (en) Medicament
Kang et al. Fulminating systemic capillary leak syndrome with lymphocytosis and hypogammaglobulinemia
Geovese et al. Giardiasis as a cause of hypokalemic myopathy in congenital immunodeficiency
Eylar et al. Suppression and reversal of allergic encephalomyelitis in rhesus monkeys with basic protein and peptides
Schou et al. Use of propranolol during lithium treatment: an enquiry and a suggestion
Strian et al. Anxiety Depression in Affective Disorders
Kastin et al. DSIP-like immunoreactivity in the developing rat brain
US20250281568A1 (en) Method for treating or preventing drug-induced liver injury with peptide composition